13771-71-6

Usage

Uses

Used in Pharmaceutical Industry:
(5-Chloro-1-benzothiophen-2-yl)methanol is used as a reagent for the preparation of pharmacologically active benzo[b]thiophene derivatives. These derivatives are known for their diverse biological activities, including potential applications in the development of new drugs targeting various diseases and conditions.
The compound's role as a reagent is crucial in the synthesis of these active derivatives, which can then be further modified or studied for their therapeutic properties. Its use in the pharmaceutical industry is primarily due to its ability to contribute to the creation of novel chemical entities with potential medicinal value.

Upstream product

• 20532-33-6 5-chlorobenzothiophene 
• 28540-51-4 5-chlorobenzo[b]thiophene-2-carboxaldehyde 
• 35212-96-5 5-chloro-2-benzo[b]thiophenecarboxylic acid methyl ester 
• 13771-67-0 ethyl 5-chlorobenzo[b]thiophene-2-carboxylate 

Downstream Products

• 99592-53-7 2-bromomethyl-5-chlorobenzo[b]thiophene 

Relevant academic research and scientific papers

N-(1-HYDROXY-3-(PYRROLIDINYL)PROPAN-2-YL)PYRROLIDINE-3-CARBOXAMIDE DERIVATIVES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS

Described herein are compounds of Formula I, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and compounds I for use to treat or prevent diseases or conditions associated with the enzyme glucosylceramide synthase (GCS).

Potent, orally active aldose reductase inhibitors related to zopolrestat: Surrogates for benzothiazole side chain

A broad structure-activity program was undertaken in search of effective surrogates for the key benzothiazole side chain of the potent aldose reductase inhibitor, zopolrestat (1). A structure-driven approach was pursued, which spanned exploration of three areas: (1) 5/6 fused heterocycles such as benzoxazole, benzothiophene, benzofuran, and imidazopyridine; (2) 5- membered heterocycles, including oxadiazole, oxazole, thiazole, and thiadiazole, with pendant aryl groups, and (3) thioanilide as a formal equivalent of benzothiazole. Several benzoxazole- and 1,2,4-oxadiazole- derived analogues were found to be potent inhibitors of aldose reductase from human placenta and were orally active in preventing sorbitol accumulation in rat sciatic nerve, in an acute test of diabetic complications. 3,4-Dihydro-4- oxo-3-[(5,7-difluoro-2-benzoxazolyl)methyl]-1-phthalazineacetic acid (124) was the best of the benzoxazole series (IC50 = 3.2 x 10-9 M); it suppressed accumulation of sorbitol in rat sciatic nerve by 78% at an oral dose of 10 mg/kg. Compound 139, 3,4-dihydro-4-oxo-3-[[(2-fluorophenyl)-1,2,4- oxadiazol-5-yl]methyl]-1-phthalazineacetic acid, with IC50 -8 M, caused a 69% reduction in sorbitol accumulation in rat sciatic nerve at an oral dose of 25 mg/kg. The thioanilide side chain featured in 3-[2-[[3- (trifluoromethyl)phenyl]amino]-2-thioxoethyl]-3,4-dihydro-4-oxo-1- phthalazineacetic acid (195) proved to be an effective surrogate for benzothiazole. Compound 195 was highly potent in vitro (IC50 = 5.2 x 10-8 M) but did not show oral activity when tested at 100 mg/kg. Additional structure-activity relationships encompassing a variety of heterocyclic side chains are discussed.

Esters and thiolesters of benzothienyl acids

Esters and thiolesters of benzothienyl acids, intermediates thereof, synthesis thereof, and the use thereof for the control of pests.